Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Dev Neurobiol. 2018 Aug 31;78(11):1117–1130. doi: 10.1002/dneu.22634

Figure 4:

Figure 4:

Western blot quantifications of post-PTZ expression of KCC2 and p-KCC2 (S940). (A) Representative western blots for KCC2 (B) p-KCC2 (S940) and their respective actins. At 24h, KCC2 upregulation was significant in PTZ only treatment group compared to control, +PB group and +PB+BTN group (bar graph in A). No significant change in p-KCC2 (S940) post-PTZ or post-treatment was detected (bar graph in B). (C) Ratio of p-KCC2 (S940)/ KCC2 24h post-PTZ showed stable ratios. (D) Ratio of p-KCC2 (S940)/ KCC2 2h post-PTZ showed stable ratios. (E) Mean KCC2 and p-KCC2 (S940) percent of control showed a temporal upregulation of KCC2. Sample size: n=32 for 24h data, n=20 for 2h data. Between groups: #P < 0.05, ##P < 0.01, ###P ≤ 0.001, independent t-tests & one-way ANOVA with Bonferroni post-hoc correlations.